Latest close: below its 200-day averageSep 8, 2026what changed →
Is the price fair?
What PEN's price assumes
Penumbra, Inc. trades at 73.6× earnings against 30.9× for the median Medical Devices name, more expensive than its own group.
73.6
Trailing P/E · Medical Devices median 30.9 · 2.38× the median: the market pays up for this one
- Price / sales
- 8.93
Price / sales · as of 2026-Q1
- Free cash flow yield
- 1.7%
Free cash flow yield · Medical Devices median 3.9%
- Growth the price implies
- +20%
Growth the price implies · The price pays for +20% free cash flow growth a year for a decade; revenue has grown +18% a year over the last three.
Details›
- Price / book2026-Q1
- 8.81
- Healthcare median P/E362 names
- 29.9
- Medical Devices median P/E39 names
- 30.9
- Free cash flow, trailing twelve months
- $213M
- Market capitalisation
- $12.5B
- 3-year revenue growth
- +18%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Medical Devices
Ranks #12 of 29 by Smart Score